In 2021, Sotorasib became the first KRAS G12C inhibitor to gain approval, revolutionizing the treatment of NSCLC.374–393 The KRAS gene had long been considered an “undruggable” target, and the approval of Sotorasib marked a significant milestone in precision medicine, offering hope in an area previously deemed unattainable. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.